Tired T cells

TSRI researchers find that the protein PTPN22 plays a role in “T cell exhaustion,” in which the body dampens the immune system

Register for free to listen to this article
Listen with Speechify
LA JOLLA, Calif.—T cell exhaustion is a phenomenon that occurs when the body dampens the immune system in the face of a virus or tumor (such as HIV infection) has taken hold and overwhelmed it. Normally in the face of a health invader, the immune system floods the problem areas with T cells, or T lymphocytes, white blood cells that can help fend off infected or damaged cells. The reason the body can put on the breaks and halt an immune response, as noted by TSRI Professor Linda Sherman, is that “T lymphocytes are very destructive, so if the virus is there to stay, the body wants the immune system to shut off to stop doing damage to the organism.”
Sherman was senior author of a new study examining this phenomenon and the protein responsible for hampering the immune system. The study, “PTPN22 contributes to exhaustion of T cell lymphocytes during chronic viral infection,” appeared in Proceedings of the National Academy of Sciences.
The protein in question is PTPN22 (protein tyrosine phosphatase nonreceptor type 22 gene), which is expressed in all immune cells. As noted in the paper, PTPN22 is responsible for “suppression of T cell receptor signaling and promoting efficient production of type I interferons (IFN-I) by myeloid cells.”
Individuals who have an altered form of this protein have a significantly increased risk for type 1 diabetes and other autoimmune diseases; the Genetics Home Reference of the U.S. National Library of Medicine cites rheumatoid arthritis, systemic lupus erythematosus and Graves disease as conditions that arise from abnormal copies of this gene and its protein.
Given how PTPN22 affects the immune system, Sherman and her colleagues wondered if a lack of the protein could consequently prevent the immune system from triggering T cell exhaustion. They sought to answer that question using mouse models infected with a clone of lymphocytic choriomeningitis virus (LCMV), which results in chronic infections similar to HIV and hepatitis. Mice without PTPN22 were able to clear the LCMV infections, but mice with PTPN22 presented with chronic infection and signs of T cell exhaustion.
“The animals deficient in the PTPN22 protein shrugged off the virus very quickly, rather than having the immune system shut down the way it normally does when it encounters this virus,” added Sherman.
“PTPN22 increases the production of IFN-β following infection, resulting in increased expression of the cAMP response element modulator (CREM) in CD4 T lymphocytes. CREM prevents production of IL-2, thereby contributing to T cell exhaustion and chronic viral infection … Mice deficient in PTPN22 resist chronic viral infection with lymphocytic choriomeningitis virus clone 13 (LCMV cl13),” the abstract notes. “The numbers and function of viral-specific CD4 T lymphocytes is greatly enhanced, whereas expression of the IFNβ-induced IL-2 repressor, cAMP-responsive element modulator (CREM) is reduced. Reduction of CREM expression in wild-type CD4 T lymphocytes prevents the loss of IL-2 production by CD4 T lymphocytes during infection with LCMV cl13.”
Moving forward, the team plans to study PTPN22's role in other cells as well, with Sherman noting that “We have to understand what’s going on so we can take advantage of that to make new types of drugs.”
Other authors of this study included Christian J. Maine, John R. Teijaro and Kristi Marquardt, all of TSRI at the time of the study.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue